This is a preview of subscription content, log in via an institution to check access.
Notes
eribulin for advanced breast cancer; everolimus for moderately differentiated pancreatic neuroendocrine carcinomas; pemetrexed for maintenance treatment of advanced non-squamous non-small cell lung cancer (NSCLC); pemetrexed for second line treatment of advanced non-squamous NSCLC; and regorafenib for advanced gastro-intestinal stromal tumours after failure with imatinib and sunitinib.
Reference
NHS England. Update on the Cancer Drugs Fund. Internet Document : 21 May 2015. Available from: URL: http://www.england.nhs.uk/2015/05/21/cdf-may-update/
Rights and permissions
About this article
Cite this article
Cancer Drugs Fund list update. PharmacoEcon Outcomes News 729, 34 (2015). https://doi.org/10.1007/s40274-015-2191-x
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40274-015-2191-x